Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsJohn P. Cogswell, Stacie M. Goldberg, Ashok K Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
Estimating the term…
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
A method of treating a a hepatocellular carcinoma (HCC) in a human subject in need thereof, comprising administering to the subject 1 mg/kg of nivolumab and 3 mg/kg of ipilimumab every 3 weeks for 4 cycles, followed by subsequently administering the nivolumab alone.
A method of treating a hepatocellular carcinoma (HCC) in a human subject in need thereof comprising administering to the subject 1 mg/kg of nivolumab and 3 mg/kg of ipilimumab every 3 weeks for 4 cycles, followed by subsequently administering the nivolumab alone;
Dependencies are inferred from the claim text.